Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.46 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10890772 | 0.98 | KDM4C (0.49) | KDM4CKDM4APHF8KDM2ADEGS1 | |
| SCHEMBL24496288 | 0.98 | KDM4C (0.49) | KDM4CKDM4APHF8KDM2ADEGS1 | |
| SCHEMBL12188679 | 0.98 | KDM4C (0.49) | KDM4CKDM4APHF8KDM2ADEGS1 | |
| SCHEMBL23640057 | 0.98 | KDM4C (0.49) | KDM4CKDM4APHF8KDM2ADEGS1 | |
| SCHEMBL10290720 | 0.98 | KDM4C (0.49) | KDM4CKDM4APHF8KDM2ADEGS1 | |
| SCHEMBL13223739 | 0.93 | LMNA (0.44) | KDM4CKDM4APHF8KDM2ADEGS1 | |
| SCHEMBL12299087 | 0.92 | LMNA (0.48) | KDM4CKDM4APHF8KDM2ADEGS1 | |
| SCHEMBL1709869 | 0.83 | — | — | |
| SCHEMBL9437025 | 0.83 | LMNA (0.40) | KDM4CKDM4APHF8KDM2ADEGS1 | |
| SCHEMBL7753090 | 0.83 | LMNA (0.57) | LMNAMEN1KMT2AFAAHMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-11-28 | — | — | US | disclosed |
| EP-4223309-A1 | COMBINATION THERAPY WITH CONTROLLED-RELEASE CNP AGONISTS | Ascendis Pharma Growth Disorders A/S (DK) | 2023-08-09 | — | — | EP | disclosed |
| EP-3518930-B1 | COMBINATION THERAPY WITH CONTROLLED-RELEASE CNP AGONISTS | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2023-03-08 | — | — | EP | disclosed |
| WO-2023283831-A1 | VIRUS MAIN PROTEASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE | 上海药明康德新药开发有限公司 | 2023-01-19 | — | — | WO | disclosed |
| US-20220218829-A1 | NUCLEIC ACID CONJUGATES AND USES THEREOF | TRANSLATE BIO MA, INC. (US) | 2022-07-14 | — | — | US | disclosed |
| US-20210214316-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2021-07-15 | — | — | US | disclosed |
| EP-3831841-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T Global Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2021097046-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20200360523-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-11-19 | — | — | US | disclosed |
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | LEHMANN LUTZ (DE) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214316-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | KDM4C 2613/4885KDM4A 1999/4885PHF8 1968/4885 |
| US-20200360523-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | KDM4C 2613/4885KDM4A 1999/4885PHF8 1968/4885 |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | KDM4C 2613/4885KDM4A 1999/4885PHF8 1968/4885 |
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | CYP4B1, CYP2B6, UGT2B7 | KDM4C 1225/4885KDM4A 1165/4885PHF8 2201/4885 |
| US-20220218829-A1 | NUCLEIC ACID CONJUGATES AND USES THEREOF | FOLR1, SLC19A1, FOLR2 | KDM4C 3225/4885KDM4A 3986/4885PHF8 2723/4885 |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | KDM4C 2613/4885KDM4A 1999/4885PHF8 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.